Metis and Eli Lilly Sign 1.1B Drug Deal
Metis TechBio has partnered with Eli Lilly in a deal worth up to 1.1 billion dollars to develop AI-driven drug delivery technologies. The Chinese biotech will use its proprietary platform to improve LNP-based therapies.
Xurve View
Insights:
Xurve View
Eli Lilly & Co signed a $1.1B drug-delivery partnership with Metis TechBio on Monday morning. The agreement focuses on advancing next-generation lipid nanoparticle architectures for targeted therapies. The collaboration bolsters Eli Lilly's pipeline in advanced biotechnology.
